Long­wood launch­es start­up Solu with drug can­di­dates from GSK and $31M to start

Long­wood Fund’s Christoph West­phal, the co-found­ing in­vestor be­hind the likes of Al­ny­lam, TScan and Tome Bio­sciences, is out with an­oth­er new biotech whose pipeline de­rives from GSK.

Boston-based Solu Ther­a­peu­tics pulled back the cur­tains on Tues­day with $31 mil­lion in seed cap­i­tal and drug can­di­dates in-li­censed from GSK. The biotech be­gins with a fo­cus on hema­to­log­i­cal ma­lig­nan­cies and an­tic­i­pates en­ter­ing the clin­ic with­in two years, co-founder and CEO David Don­abe­di­an said in a press re­lease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER